Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting (Q33349204)

26 July 2017

title

Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting (English)

1 reference

26 July 2017

0 references

anti-retroviral agent

0 references

Motasim Badri

1

0 references

Stephen Lawn

series ordinal

2

object named as

Stephen D Lawn

1 reference

26 July 2017

3

Robin Wood

1 reference

26 July 2017

publication date

4 July 2008

1 reference

26 July 2017

published in

BMC Infectious Diseases

1 reference

26 July 2017

volume

8

1 reference

26 July 2017

page(s)

89

1 reference

Creative Commons Attribution 2.0 Generic

26 July 2017

copyright license

start time

4 July 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2459184

Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2459184

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2459184

A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2459184

Cost-effectiveness of highly active antiretroviral therapy in South Africa

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2459184

The dissociation between virological and immunological responses to HAART.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2459184

Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2459184

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2459184

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2459184

Evaluating a model for monitoring the virological efficacy of antiretroviral treatment in resource-limited settings

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-89

Explaining, Predicting, and Treating HIV-Associated CD4 Cell Loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-89

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-89

Virological rebound after suppression on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-89

Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-89

Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-89

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-89

Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2459184

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

31 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-89

Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

21 January 2018

1 reference

12 December 2020

Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen

1 reference

12 December 2020

Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease

1 reference

12 December 2020

Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil

1 reference

12 December 2020

Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2334-8-89

1 reference

26 July 2017

1 reference

26 July 2017

1 reference